Shandong Kexing Bioproducts Co,.Ltd (688136.SS)

CNY 20.64

(5.84%)

Market Cap (In CNY)

3.57 Billion

Revenue (In CNY)

1.25 Billion

Net Income (In CNY)

-190.29 Million

Avg. Volume

818.8 Thousand

Currency
CNY
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
10.61-22.82
PE
-
EPS
-
Beta Value
1.2870898
ISIN
INE711A01022
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Yan Qing Zhao
Employee Count
-
Website
http://www.kexing.com
Ipo Date
2020-12-14
Details
Shandong Kexing Bioproducts Co., Ltd. engages in the research and development, production, and sale of recombinant protein therapeutics and microbiota agents. Its products include recombinant human erythropoietin injections, recombinant human interferon a1b injections, recombinant human granulocyte stimulating factor injections, and clostridium butyricum double live bacteria powder and capsules. The company was founded on August 22, 1997 and is headquartered in Jinan, China.